Bausch Health Companies Inc. [NYSE: BHC] closed the trading session at $19.92 on 11/16/20. The day’s price range saw the stock hit a low of $19.4513, while the highest price level was $20.13. The company report on November 16, 2020 that Bausch Health Announces Investigational In Vitro Data Indicating Complete Inactivation Of SARS-CoV-2 With LUMIFY® And BESIVANCE® Eye Drops Preserved With Benzalkonium Chloride.
LAVAL, Quebec, Nov. 16, 2020 /CNW/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and Bausch + Lomb, its leading global eye health business, announced the results of new investigational in vitro data showing that two benzalkonium chloride (BAK) preserved eye drops, LUMIFY® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops and BESIVANCE® (besifloxacin ophthalmic suspension) 0.6%, indicated complete inactivation of Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2 or COVID-19). These data were presented at the 2020 Ocular Microbiology and Immunology Group 54th Annual Meeting that took place virtually on Friday, Nov. 13, 2020.
“Our team presented investigational data that evaluated the in vitro antiviral activity of LUMIFY and BESIVANCE against SARS-CoV-2, and the results indicated complete inactivation of the virus,” said Joseph C. Papa, chairman and CEO, Bausch Health. “The clinical relevance of this in vitro data is not known, and our intention is to further review these data to determine next steps, including potential discussions with regulatory agencies around the world.”.
The stocks have a year to date performance of -33.42 percent and weekly performance of 3.97 percent. The stock has been moved at 11.10 percent over the last six months. The stock has performed 16.42 percent around the most recent 30 days and changed 14.95 percent over the most recent 3-months.
If compared to the average trading volume of 4.35M shares, BHC reached to a volume of 3760898 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Bausch Health Companies Inc. [BHC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BHC shares is $26.47 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BHC stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Bausch Health Companies Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 17, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $64 to $50. The new note on the price target was released on August 24, 2020, representing the official price target for Bausch Health Companies Inc. stock. Previously, the target price had yet another raise from $50 to $64, while H.C. Wainwright kept a Buy rating on BHC stock. On June 17, 2020, analysts increased their price target for BHC shares from 50 to 64.
The Average True Range (ATR) for Bausch Health Companies Inc. is set at 0.82, with the Price to Sales ratio for BHC stock in the period of the last 12 months amounting to 0.85. The Price to Book ratio for the last quarter was 12.07, with the Price to Cash per share for the same quarter was set at 2.85. Price to Free Cash Flow for BHC in the course of the last twelve months was 10.49 with Quick ratio for the last quarter at 0.90.
BHC stock trade performance evaluation
Bausch Health Companies Inc. [BHC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.97. With this latest performance, BHC shares gained by 16.42% in over the last four-week period, additionally plugging by 11.10% over the last 6 months – not to mention a drop of -30.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BHC stock in for the last two-week period is set at 64.49, with the RSI for the last a single of trading hit 69.80, and the three-weeks RSI is set at 62.35 for Bausch Health Companies Inc. [BHC]. The present Moving Average for the last 50 days of trading for this stock 16.91, while it was recorded at 19.47 for the last single week of trading, and 18.24 for the last 200 days.
Bausch Health Companies Inc. [BHC]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bausch Health Companies Inc. [BHC] shares currently have an operating margin of +15.45 and a Gross Margin at +50.62. Bausch Health Companies Inc.’s Net Margin is presently recorded at -20.79.
Return on Total Capital for BHC is now 4.88, given the latest momentum, and Return on Invested Capital for the company is -6.78. Return on Equity for this stock declined to -94.20, with Return on Assets sitting at -5.39. When it comes to the capital structure of this company, Bausch Health Companies Inc. [BHC] has a Total Debt to Total Equity ratio set at 2,463.59. Additionally, BHC Total Debt to Total Capital is recorded at 96.10, with Total Debt to Total Assets ending up at 77.34. Long-Term Debt to Equity for the company is recorded at 2,342.52, with the Long-Term Debt to Total Capital now at 91.38.
Reflecting on the efficiency of the workforce at the company, Bausch Health Companies Inc. [BHC] managed to generate an average of -$82,396 per employee. Receivables Turnover for the company is 4.64 with a Total Asset Turnover recorded at a value of 0.26.Bausch Health Companies Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.20.
Earnings per share (EPS) analysis for Bausch Health Companies Inc. [BHC] stock
With the latest financial reports released by the company, Bausch Health Companies Inc. posted 1.12/share EPS, while the average EPS was predicted by analysts to be reported at 1.15/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -2.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BHC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bausch Health Companies Inc. go to 3.40%.
Bausch Health Companies Inc. [BHC]: Insider Ownership positions
There are presently around $4,543 million, or 66.80% of BHC stock, in the hands of institutional investors. The top three institutional holders of BHC stocks are: PAULSON & CO. INC. with ownership of 25,839,035, which is approximately 0% of the company’s market cap and around 2.30% of the total institutional ownership; VALUEACT HOLDINGS, L.P., holding 17,931,594 shares of the stock with an approximate value of $357.2 million in BHC stocks shares; and GLENVIEW CAPITAL MANAGEMENT, LLC, currently with $297.96 million in BHC stock with ownership of nearly -4.388% of the company’s market capitalization.
Positions in Bausch Health Companies Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 160 institutional holders increased their position in Bausch Health Companies Inc. [NYSE:BHC] by around 34,520,509 shares. Additionally, 135 investors decreased positions by around 39,257,136 shares, while 63 investors held positions by with 154,265,239 shares. The mentioned changes placed institutional holdings at 228,042,884 shares, according to the latest SEC report filing. BHC stock had 57 new institutional investments in for a total of 14,347,472 shares, while 37 institutional investors sold positions of 4,922,362 shares during the same period.